Rocklatan header logo
MENU CLOSE

For the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

Advancing IOP control in a single bottle1,2

Once-daily Rocklatan® is the first and only fixed-dose combination of a prostaglandin + ROCK inhibitor that provides patients with superior efficacy vs its individual components (including latanoprost) at all timepoints1,2 


Rocklatan®: A powerful ROCK inhibitor1,2

Over 60% of Rocklatan® patients reached IOP reductions of 30% or more—nearly twice as many as latanoprost2


Making a difference for more glaucoma patients

People living with glaucoma have a lot to manage. According to a National Glaucoma Impact Survey of 1,548 adult glaucoma patients, one-third reported they missed an eye drop dose at least two to three times per month.6

Identify the right ROCK inhibitor for your glaucoma patient

Download ROCK Inhibitor Differentiator

Empower your patients with more information about the benefit of starting a ROCK inhibitor

Download Patient Brochure


Resources created specifically for eye care providers like you

Become a

Access engaging content, educational resources, and Aerie research for glaucoma care and beyond.


IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.

Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.

Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.

Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.

Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.

Bacterial keratitis has been reported with multiple-dose containers of topical ophthalmic products inadvertently contaminated by patients.

Remove contact lenses prior to administration and reinsert 15 minutes after administration.

Adverse reactions

The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

INDICATIONS AND USAGE

Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

Please click here for full prescribing information for Rocklatan® Solution

To report Suspected Adverse Reactions, contact Aerie Pharmaceuticals, Inc. at 1-855-740-1924 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.

Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.

Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.

Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.

Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.

Bacterial keratitis has been reported with multiple-dose containers of topical ophthalmic products inadvertently contaminated by patients.

Remove contact lenses prior to administration and reinsert 15 minutes after administration.

Adverse reactions

The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

INDICATIONS AND USAGE

Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

Please click here for full prescribing information for Rocklatan® Solution

To report Suspected Adverse Reactions, contact Aerie Pharmaceuticals, Inc. at 1-855-740-1924 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References:

  1. Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2020.
  2. Asrani, S., Bacharach, J., Holland, E. et al. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2. Adv Ther 37, 1620–1631 (2020).
  3. Higginbotham E. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1-9
  4. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005 May;112(5):863-8.
  5. Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011 Jan;59 Suppl(Suppl1):S93-6.
  6. Glaucoma Research Foundation. National Glaucoma Patient and Caregiver Survey. September 5, 2019.